# NCT02113982 (NCT02113982)

> Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

No report yet. It can be ordered.

- Drugs tested: tagraxofusp
- Indication: blastic plasmacytoid dendritic cell neoplasm or AML

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02113982
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Stemline Therapeutics, Inc.
- Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Acute Myeloid Leukemia (AML)
- Interventions: Tagraxofusp
- Enrollment: 138
- Primary outcome: MTD (Stage 1)
- Primary outcome: CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)

## Indexed commentary on NCT02113982 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02113982